Document is current

Article History

Accepted: 24 July 2025

First Online: 7 August 2025

Declarations

:

: The authors received no funding for the development of this work. Medical writing and creative and editorial assistance were provided by Ogilvy Health UK and funded by UCB. The open access fee was paid by UCB.

: K.D. has received honorarium from Crossject, Neurelis, and UCB for participating in advisory board meetings. AS has received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Neuraxpharm, Takeda, UCB Pharma, and UNEEG Medical. J.C.C. serves as an advisory board member for Neurelis, serves as a consultant for Crossject, and has received research grants from PrevEp and Allaysis. R.R., C.L., and H.C. are employed by UCB.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: K.D.: conceptualization, writing—review and editing. A.S.: conceptualization, writing—review and editing. R.R.: conceptualization, writing—review and editing. C.L.: conceptualization, writing—review and editing, funding acquisition. H.C.: conceptualization, writing—review and editing. J.C.C.: conceptualization, writing—review and editing. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.